This is in line with clinical trial data as exemplified by the pooled analysis of three clinical trials by Puzanv et al., which concluded in favour of the use of pembrolizumab in the setting of advanced melanoma, regardless of patients’ BRAF V600E/K mutation status [29]. This evidence concerns the gene BRAF and melanoma.